Ryan Travis, MD
Psychiatry · Fremont, OHNPI 1649302621
Payments from drug & device makers
Across 146 payments — averaging $20.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$490
- Teva Pharmaceuticals USA, Inc.$307
- Alkermes, Inc.$276
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$255
- Axsome Therapeutics, Inc.$229
- Vanda Pharmaceuticals Inc.$198
- plus $1K from 13 others
What the payments were for
- Food & beverage$2,76494%
- Education$1906%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 27 | $490 |
| Teva Pharmaceuticals USA, Inc. | 14 | $307 |
| Alkermes, Inc. | 13 | $276 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $255 |
| Axsome Therapeutics, Inc. | 9 | $229 |
| Vanda Pharmaceuticals Inc. | 11 | $198 |
| Lundbeck LLC | 8 | $197 |
| Otsuka America Pharmaceutical, Inc. | 10 | $188 |
| Johnson & Johnson | 8 | $177 |
| Supernus Pharmaceuticals, Inc. | 6 | $125 |
| Neurocrine Biosciences, Inc. | 6 | $110 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $109 |
| Ironshore Pharmaceuticals Inc. | 5 | $104 |
| Corium, LLC | 5 | $65 |
| Avanir Pharmaceuticals, Inc. | 3 | $63 |
| Sage Therapeutics, LLC | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Neos Therapeutics, LP | 1 | $14 |
| Tris Pharma Inc | 1 | $12 |
How this compares
$2,954 in reported general payments places this provider in the 80th percentile of 1,119 psychiatry providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 22 | $175,866 |
| RexultiBrexpiprazole | 66 | $116,708 |
| TrintellixVortioxetine Hydrobromide | 51 | $46,005 |
| VraylarCariprazine Hcl | 16 | $32,534 |
| Aripiprazole | 125 | $12,730 |
| BelsomraSuvorexant | 18 | $8,941 |
| Paliperidone ErPaliperidone | 30 | $8,833 |
| Lurasidone Hcl | 14 | $6,640 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 117 | $4,860 |
| Modafinil | 18 | $3,893 |
| Lisdexamfetamine Dimesylate | 17 | $3,845 |
| Divalproex Sodium ErDivalproex Sodium | 32 | $3,626 |
| Vilazodone Hcl | 19 | $3,522 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 44 | $3,429 |
| Quetiapine Fumarate | 116 | $3,276 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $110 | $175,86622 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $188 | $116,70866 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $109 | $46,00551 claims |
| AbbVieVraylar | $490 | $32,53416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,119 psychiatry providers in Ohio.
Other psychiatry in Fremont
- Shishuka MalhotraCanton$15M
- Henry NasrallahCincinnati$3.8M
- Otto DuenoDayton$3.1M
- Diab AlmhanaAvon Lake$2.7M
- Mohamed Abdel AzizWest Chester$2.6M
- Fred RomeoColumbus$2.3M
- Mark WoyshvilleMiddleburg Heights$2.2M
- Amita PatelDayton$2.1M
- Caleb AdlerCincinnati$2M
- Richard SandersDayton$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.